Abstract
The 1980s comprised a period in which our understanding of the immunology of infection and, specifically, severe conditions known as ARDS, was being expanded. It was the 1980 classic study by Hammerschmidt and colleagues1 in Lancet that described the association between complement activation and elevated plasma C3a levels with ARDS that alerted many clinicians to this syndrome and an ability to better diagnose it. Management was an altogether different matter.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
